Ewing's Sarcoma is an aggressive pediatric bone cancer common in teenagers and young adults.  It is potentially the most lethal of all bone tumors with a 30% survival rate. Ajulemic Acid (AJA) offers a potential solution to this problem.  Our data show this compound successfully kills Ewing's sarcoma cells as well as several other pediatric tumor cell lines in vitro, and we have seen complete tumor regression in approximately 33% of our treated mice. Our data demonstrate that ajulemic acid inhibits the migration of tumor cells and endothelial cells, the cells that line blood vessels and direct their growth.  Our aim for this study is to determine the mechanism through which AJA inhibits angiogenesis by looking specifically at its effects on Vascular Endothelial Growth Factor (VEGF) levels.  VEGF is a protein secreted by cells to promote angiogenesis, our hypothesis was VEGF is to be inhibited by AJA.

Effects of ajulemic acid on VEGF production: Relevance to angiogenic potential in Ewing's sarcoma

245th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.